KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Liabilities and Shareholders Equity (2018 - 2025)

Esperion Therapeutics' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $465.9 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 35.5% year-over-year to $465.9 million; the TTM value through Dec 2025 reached $1.5 billion, up 8.51%, while the annual FY2025 figure was $465.9 million, 35.5% up from the prior year.
  • Liabilities and Shareholders Equity reached $465.9 million in Q4 2025 per ESPR's latest filing, up from $364.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $465.9 million in Q4 2025 to a low of $205.8 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $308.6 million, with a median of $313.5 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 35.02% in 2022, then skyrocketed 67.07% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $381.6 million in 2021, then tumbled by 35.02% to $247.9 million in 2022, then fell by 17.0% to $205.8 million in 2023, then soared by 67.07% to $343.8 million in 2024, then skyrocketed by 35.5% to $465.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Liabilities and Shareholders Equity are $465.9 million (Q4 2025), $364.0 million (Q3 2025), and $347.1 million (Q2 2025).